Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 6/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 4/20 | 0.42 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | CA4 | P22748 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29714271 | 1.00 | TDP1 (0.54) | TDP1RXFP1KDM4ENPSR1ALDH1A1 | |
| SCHEMBL16077775 | 0.80 | TDP1 (0.54) | TDP1RXFP1KDM4ENPSR1ALDH1A1 | |
| SCHEMBL3697579 | 0.80 | TDP1 (0.54) | TDP1RXFP1KDM4ENPSR1ALDH1A1 | |
| SCHEMBL3694105 | 0.78 | TDP1 (0.52) | TDP1RXFP1KDM4ENPSR1ALDH1A1 | |
| Potassium Ion SCHEMBL3703885 | 0.78 | TDP1 (0.52) | TDP1RXFP1KDM4ENPSR1ALDH1A1 | |
| SCHEMBL3703888 | 0.78 | TDP1 (0.52) | TDP1RXFP1KDM4ENPSR1ALDH1A1 | |
| SCHEMBL3694520 | 0.78 | TDP1 (0.52) | TDP1RXFP1KDM4ENPSR1ALDH1A1 | |
| SCHEMBL3694109 | 0.78 | TDP1 (0.52) | TDP1RXFP1KDM4ENPSR1ALDH1A1 | |
| Lithium Ion SCHEMBL3694518 | 0.78 | TDP1 (0.52) | TDP1RXFP1KDM4ENPSR1ALDH1A1 | |
| SCHEMBL27933878 | 0.78 | KDM4E (0.56) | TDP1KDM4EALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7888 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| EP-4694892-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TOPOISOMERASE INHIBITOR, A SPLICING INHIBITOR SULFONAMIDE, OR A KIF18 INHIBITOR | Ideaya Biosciences, Inc. (US) | 2026-02-18 | — | — | EP | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| WO-2024216145-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TOPOISOMERASE INHIBITOR, A SPLICING INHIBITOR SULFONAMIDE, OR A KIF18 INHIBITOR | IDEAYA BIOSCIENCES, INC. (US) | 2024-10-17 | — | — | WO | claimed |
| US-20240343697-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2024-10-17 | — | — | US | claimed |
| EP-2796112-B2 | Degradable implantable medical devices | ELIXIR MEDICAL CORP (US) | 2023-08-09 | — | — | EP | claimed |
| US-20230190707-A1 | COMPOSITIONS AND METHODS FOR ENHANCING CANCER IMMUNOTHERAPY | FRED HUTCHINSON CANCER CENTER (US) | 2023-06-22 | — | — | US | claimed |
| EP-4149483-A2 | COMPOSITIONS AND METHODS FOR ENHANCING CANCER IMMUNOTHERAPY | Fred Hutchinson Cancer Center (US) | 2023-03-22 | — | — | EP | claimed |
| US-11345956-B2 | Methods and compositions related to prostate cancer therapeutics | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-05-31 | — | — | US | claimed |
| US-11207289-B2 | Use of benzofuran lignans to induce IL-25 expression and suppress mammary tumor metastasis | ACADEMIA SINICA (TW) | 2021-12-28 | — | — | US | claimed |
| US-20040092583-A1 | Treatment for inhibiting neoplastic lesions | SHANAHAN-PRENDERGAST ELIZABETH (IE) | 2004-05-13 | — | — | US | claimed |
| WO-2004028406-A1 | DRUG RELEASE FROM ANTITHROMBOGENIC MULTI-LAYER COATED STENT | MEDIPLEX CORPORATION (KR) | 2004-04-08 | — | — | WO | claimed |
| US-6702850-B1 | Multi-coated drug-eluting stent for antithrombosis and antirestenosis | MEDIPLEX CORPORATION KOREA (KR) | 2004-03-09 | — | — | US | claimed |
| EP-1351678-A2 | TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS | Shanahan-Prendergast, Elizabeth (IE) | 2003-10-15 | — | — | EP | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| US-20030072794-A1 | Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes | REGULON, INC. | 2003-04-17 | — | — | US | claimed |
| EP-1292284-A2 | ENCAPSULATION OF POLYNUCLEOTIDES AND DRUGS INTO TARGETED LIPOSOMES | Boulikas, Teni (US) | 2003-03-19 | — | — | EP | claimed |
| WO-2002053138-A2 | TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS | SHANAHAN-PRENDERGAST ELISABETH (IE) | 2002-07-11 | — | — | WO | claimed |
| WO-2001093836-A2 | ENCAPSULATION OF POLYNUCLEOTIDES AND DRUGS INTO TARGETED LIPOSOMES | BOULIKAS TENI (US) | 2001-12-13 | — | — | WO | claimed |
| WO-2000040269-A2 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF DISEASED TISSUES | LEE CLARENCE C (US) | 2000-07-13 | — | — | WO | claimed |